Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Net Income towards Common Stockholders (2021 - 2025)

SAB Biotherapeutics' Net Income towards Common Stockholders history spans 5 years, with the latest figure at -$15.1 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 32.81% year-over-year to -$15.1 million; the TTM value through Dec 2025 reached -$42.5 million, down 24.65%, while the annual FY2025 figure was -$47.8 million, 40.04% down from the prior year.
  • Net Income towards Common Stockholders reached -$15.1 million in Q4 2025 per SABSW's latest filing, down from -$12.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $1.4 million in Q1 2021 to a low of -$22.9 million in Q4 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$7.7 million, with a median of -$7.2 million recorded in 2022.
  • Peak YoY movement for Net Income towards Common Stockholders: crashed 845.93% in 2023, then skyrocketed 50.15% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$11.6 million in 2021, then soared by 31.83% to -$7.9 million in 2022, then crashed by 190.26% to -$22.9 million in 2023, then surged by 50.15% to -$11.4 million in 2024, then plummeted by 32.81% to -$15.1 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Net Income towards Common Stockholders are -$15.1 million (Q4 2025), -$12.1 million (Q3 2025), and -$10.1 million (Q2 2025).